Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer
Abstract Background To assess the oncologic outcomes of radiation therapy (RT) combined with maximal androgen blockade (MAB) and prostate-specific antigen (PSA) kinetics in patients with localized, high-risk prostate carcinoma (PCa). Methods Three-hundred twenty individuals with localized PCa who un...
Main Authors: | Yong Luo, Mingchuan Li, Hengzhi Qi, Jiahui Zhao, Yili Han, Yunhua Lin, Zhu Hou, Yongguang Jiang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-06-01
|
Series: | World Journal of Surgical Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12957-018-1395-5 |
Similar Items
-
Maximal androgen blockade for advanced prostate cancer
by: Rajiv Paul Mukha, et al.
Published: (2010-01-01) -
Role of maximum androgen blockade in advanced prostate cancer
by: Rajinikanth Ayyathurai, et al.
Published: (2009-01-01) -
Pretreatment serum albumin/globulin ratio as a prognostic biomarker in metastatic prostate cancer patients treated with maximal androgen blockade
by: Ning Wang, et al.
Published: (2019-01-01) -
Quality of life and results of total androgen blockade alone and with radiotherapy in the treatment of nonmetastatic prostate cancer
by: Milovanović Lela, et al.
Published: (2012-01-01) -
Orchiectomy versus combined androgen blockade in the management of advanced carcinoma prostate
by: M S Ansari, et al.
Published: (2001-01-01)